Nuffield Orthopaedic Centre

CORRECTION: BONESUPPORT's Technology to be Featured in Clinical Program at American Academy of Orthopaedic Surgeons Meeting in Chicago

Retrieved on: 
Tuesday, March 22, 2022
Recurrence, Treatment, University, Bone remodeling, Limb, Patient, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Osteomyelitis, Ankle, Hospital, CT, Standard of care, Infection, AAOS, William H. Harris (orthopaedic surgeon), MD, Quality of life, McNally, St. Michael's Hospital, Technology, Nasdaq, American Academy, Program, Trauma, Assistant professor, Foot, Antibiotics, Nightclub

BOSTON, March 22, 2022 /PRNewswire-PRWeb/ -- Today, BONESUPPORT , innovator of injectable bone grafts that change the standard of care for patients with bone infections, is announcing plans to exhibit at The American Academy of Orthopaedic Surgeons Meeting in Chicago on March 22-26 with its platform technology CERAMENT, being featured in the Clinical Program.

Key Points: 
  • BOSTON, March 22, 2022 /PRNewswire-PRWeb/ -- Today, BONESUPPORT , innovator of injectable bone grafts that change the standard of care for patients with bone infections, is announcing plans to exhibit at The American Academy of Orthopaedic Surgeons Meeting in Chicago on March 22-26 with its platform technology CERAMENT, being featured in the Clinical Program.
  • BONESUPPORT (Nasdaq Stockholm: BONEX) Holding AB (publ), is the innovator of injectable bone grafts that change the standard of care for patients with bone infections.
  • Based on the patented technology, CERAMENTTM, and backed by robust clinical evidence, BONESUPPORT delivers the first injectable combination bone substitute that promotes and protects bone healing.
  • The company is based in Lund, Sweden.

BONESUPPORT's Technology to be Featured in Clinical Program at American Academy of Orthopaedic Surgeons Meeting in Chicago

Retrieved on: 
Monday, March 21, 2022
Recurrence, Treatment, University, Bone remodeling, Limb, Patient, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Osteomyelitis, Ankle, Hospital, CT, Standard of care, Infection, AAOS, William H. Harris (orthopaedic surgeon), MD, Quality of life, McNally, St. Michael's Hospital, Technology, Nasdaq, American Academy, Program, Trauma, Assistant professor, FDA, Foot, Antibiotics, Nightclub

BOSTON, March 21, 2022 /PRNewswire-PRWeb/ --Today, BONESUPPORT , innovator of injectable bone grafts that change the standard of care for patients with bone infections, is announcing plans to exhibit at The American Academy of Orthopaedic Surgeons Meeting in Chicago on March 22-26 with its platform technology CERAMENT, being featured in the Clinical Program.

Key Points: 
  • BOSTON, March 21, 2022 /PRNewswire-PRWeb/ --Today, BONESUPPORT , innovator of injectable bone grafts that change the standard of care for patients with bone infections, is announcing plans to exhibit at The American Academy of Orthopaedic Surgeons Meeting in Chicago on March 22-26 with its platform technology CERAMENT, being featured in the Clinical Program.
  • BONESUPPORT (Nasdaq Stockholm: BONEX) Holding AB (publ), is the innovator of injectable bone grafts that change the standard of care for patients with bone infections.
  • Based on the patented technology, CERAMENTTM, and backed by robust clinical evidence, BONESUPPORT delivers the first injectable combination bone substitute that promotes and protects bone healing.
  • The company is based in Lund, Sweden and has secured FDA authorization for CERAMENT G in the U.S.

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting

Retrieved on: 
Tuesday, February 15, 2022
University of Oxford, Nuffield Orthopaedic Centre, Â, Lead, Drug Quality and Security Act, Tumor microenvironment, CUE, Board, Regulatory T cell, COVID-19, Selective, Wellcome Trust Principal Research Fellow, Lists of diseases, Securities Act of 1933, Risk, Moscone Center, Infection, Patent, Financial condition report, Research, Result, Kennedy Institute of Ethics Journal, Kennedy Institute, Nuffield Department of Population Health, Analysis, Nasdaq, Board of directors, Policy, GLOBE, Drug development, APC, Conversation, Patient, Autoimmune disease, Form 10-Q, Cancer, Food, NHS, Forward-looking statement, University, Annual report, Securities Exchange Act of 1934, FDA, PMHC cellular microarray, TCR, Pharmaceutical industry, Vaccine, Veterinary medicine, Rheumatology

Cue Biopharma entered into a strategic research collaboration with Dr. Michael Dustin and the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of its IL-2 based CUE-100 series biologics.

Key Points: 
  • Cue Biopharma entered into a strategic research collaboration with Dr. Michael Dustin and the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of its IL-2 based CUE-100 series biologics.
  • The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules.
  • This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient.
  • This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in selective T cell modulation.

ImmunOs Therapeutics Appoints Jeffrey Abbey as Chief Operating Officer, Establishes Clinical Advisory Board

Retrieved on: 
Wednesday, September 1, 2021
Newton, University, PD-1, Economics, University of Melbourne, Oncology, German Cancer Research Center, University of Oxford, Department, Molecular imaging, La Trobe University, Virology, Monash University, CD47, Therapy, PD-L1, Nuffield Orthopaedic Centre, Rheumatology, National Center for Advancing Translational Sciences, DKFZ, Doctor of Philosophy, Clinical trial, IPO, CEO, Business administration, Program, Olivia, Antibody, Business development, Immunotherapy, MBA, Coronavirus Scientific Advisory Board (Turkey), Degenerative disease, NASDAQ, COO, Nuffield Department of Population Health, Company, Brain Tumour Research, Growth, Cancer, JD, University Hospital Heidelberg, Immuno AG, Â, Neoplasm, NCT, Kidney cancer, Pharmaceutical industry, Management

September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.

Key Points: 
  • September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.
  • Under Mr. Abbeys leadership, Argos Therapeutics successfully completed an IPO on NASDAQ, as well as a pivotal Phase 3 clinical trial in kidney cancer.
  • I am looking forward to working with the team at ImmunOs and its advisory boards, said Jeffrey Abbey, MBA, JD, COO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and activates anti-tumor responses.